These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 19610615

  • 1. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
    Alshoukr F, Rosant C, Maes V, Abdelhak J, Raguin O, Burg S, Sarda L, Barbet J, Tourwé D, Pelaprat D, Gruaz-Guyon A.
    Bioconjug Chem; 2009 Aug 19; 20(8):1602-10. PubMed ID: 19610615
    [Abstract] [Full Text] [Related]

  • 2. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP, de Jong M.
    Eur J Nucl Med Mol Imaging; 2003 Aug 19; 30(8):1134-9. PubMed ID: 12768332
    [Abstract] [Full Text] [Related]

  • 3. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
    Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL.
    J Med Chem; 2003 Jul 17; 46(15):3403-11. PubMed ID: 12852770
    [Abstract] [Full Text] [Related]

  • 4. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
    Alshoukr F, Prignon A, Brans L, Jallane A, Mendes S, Talbot JN, Tourwé D, Barbet J, Gruaz-Guyon A.
    Bioconjug Chem; 2011 Jul 20; 22(7):1374-85. PubMed ID: 21662976
    [Abstract] [Full Text] [Related]

  • 5. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
    García-Garayoa E, Maes V, Bläuenstein P, Blanc A, Hohn A, Tourwé D, Schubiger PA.
    Nucl Med Biol; 2006 May 20; 33(4):495-503. PubMed ID: 16720241
    [Abstract] [Full Text] [Related]

  • 6. Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
    Janssen PJ, de Visser M, Verwijnen SM, Bernard BF, Srinivasan A, Erion JL, Breeman WA, Vulto AG, Krenning EP, de Jong M.
    Cancer Biother Radiopharm; 2007 Jun 20; 22(3):374-81. PubMed ID: 17651043
    [Abstract] [Full Text] [Related]

  • 7. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M, Berger S, Poethko T, Schwaiger M, Wester HJ.
    Bioconjug Chem; 2008 Jun 20; 19(6):1256-68. PubMed ID: 18510351
    [Abstract] [Full Text] [Related]

  • 8. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.
    J Nucl Med; 2002 Dec 20; 43(12):1650-6. PubMed ID: 12468515
    [Abstract] [Full Text] [Related]

  • 9. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M, Behr TM.
    Biopolymers; 2002 Dec 20; 66(6):399-418. PubMed ID: 12658727
    [Abstract] [Full Text] [Related]

  • 10. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
    García-Garayoa E, Bläuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, Tourwé D, Schubiger PA.
    J Nucl Med; 2002 Mar 20; 43(3):374-83. PubMed ID: 11884498
    [Abstract] [Full Text] [Related]

  • 11. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
    Emrarian I, Sadeghzadeh N, Abedi SM, Abediankenari S.
    Chem Biol Drug Des; 2018 Jan 20; 91(1):304-313. PubMed ID: 28816013
    [Abstract] [Full Text] [Related]

  • 12. Evidence of 68Ga-DOTA-NT-20.3 Uptake in Pancreatic Adenocarcinoma AsPC-1 Cell Line - in vitro Study.
    Marenco M, Lodola L, Persico MG, Frangipane V, Facoetti A, Aprile C, Hodolič M.
    Curr Pharm Biotechnol; 2018 Jan 20; 19(9):754-759. PubMed ID: 30160211
    [Abstract] [Full Text] [Related]

  • 13. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
    Roosenburg S, Laverman P, Joosten L, Eek A, Oyen WJ, de Jong M, Rutjes FP, van Delft FL, Boerman OC.
    Bioconjug Chem; 2010 Apr 21; 21(4):663-70. PubMed ID: 20302291
    [Abstract] [Full Text] [Related]

  • 14. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.
    Hillairet De Boisferon M, Raguin O, Thiercelin C, Dussaillant M, Rostène W, Barbet J, Pélegrin A, Gruaz-Guyon A.
    Bioconjug Chem; 2002 Apr 21; 13(3):654-62. PubMed ID: 12009958
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.
    J Nucl Med; 2003 Sep 21; 44(9):1469-78. PubMed ID: 12960194
    [Abstract] [Full Text] [Related]

  • 16. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
    Nock BA, Nikolopoulou A, Reubi JC, Maes V, Conrath P, Tourwé D, Maina T.
    J Med Chem; 2006 Jul 27; 49(15):4767-76. PubMed ID: 16854083
    [Abstract] [Full Text] [Related]

  • 17. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression.
    Souazé F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P.
    Cancer Res; 2006 Jun 15; 66(12):6243-9. PubMed ID: 16778199
    [Abstract] [Full Text] [Related]

  • 18. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
    Wu Z, Li L, Liu S, Yakushijin F, Yakushijin K, Horne D, Conti PS, Li Z, Kandeel F, Shively JE.
    J Nucl Med; 2014 Jul 15; 55(7):1178-84. PubMed ID: 24854793
    [Abstract] [Full Text] [Related]

  • 19. Relevant genomics of neurotensin receptor in cancer.
    Elek J, Pinzon W, Park KH, Narayanan R.
    Anticancer Res; 2000 Jul 15; 20(1A):53-8. PubMed ID: 10769634
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
    Jia Y, Shi W, Zhou Z, Wagh NK, Fan W, Brusnahan SK, Garrison JC.
    Nucl Med Biol; 2015 Nov 15; 42(11):816-23. PubMed ID: 26302836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.